RecruitingNCT05041140

Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment

Sponsor

M.D. Anderson Cancer Center

Enrollment

25 participants

Start Date

Aug 14, 2024

Study Type

OBSERVATIONAL

Conditions

Pneumonia Pulmonary Hematopoietic System--Cancer

Summary

This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD). The primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements. A secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is using a special type of MRI scan that uses inhaled xenon gas (Xe-MRI) to measure lung function in patients who have received a bone marrow or stem cell transplant and developed a lung complication called bronchiolitis obliterans syndrome (BOS) — a form of scarring that reduces airflow. **You may be eligible if...** - You are 18 or older - You received an allogeneic (donor) stem cell transplant - You have been diagnosed with bronchiolitis obliterans syndrome (BOS), are borderline for BOS (BOS 0p), or have chronic graft-versus-host disease in another organ without lung problems - You are still receiving follow-up care at MD Anderson **You may NOT be eligible if...** - You are unable to travel for follow-up care - You are unable or unwilling to give informed consent - Your disease has relapsed or your life expectancy is less than 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.